Navigation Links
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
Date:5/22/2008

BETHESDA, Md., May 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that the company will provide an update on the phase 1 clinical trial underway for its BiTE(R) antibody MT103/MEDI-538 at the 10th International Conference on Malignant Lymphomas, taking place June 4-7 in Lugano, Switzerland.

The presentation, entitled, "Anti-CD19 BiTE Antibody MT103 (MEDI-538) Induces Durable Objective Responses in Patients with Relapsed Non-Hodgkin's Lymphoma (NHL). Update from Ongoing Phase I Study MT103-104" will take place during Poster Session I from 8:00am to 6:00pm on June 5th, 2008 in the Marquee Parco Ciani. Meeting abstracts will first be available during the week of the conference.

The 10th International Conference on Malignant Lymphoma gathers 3,000 leading physicians from all over the world: hematologists, clinical oncologists, pathologists and leading researchers involved in the study and treatment of lymphoid neoplasms, including multiple myeloma and CLL.

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of kill
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
7. Micromet Announces Changes in Management Team
8. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
(Date:1/14/2014)... , January 14, 2014 ... Transfer Devices (CSTD) for hazardous drugs, today announced that it ... fourth straight year.   Equashield,s closed ... technicians, pharmacists, nurses and other medical professionals who ...
(Date:1/14/2014)... Spark Therapeutics , a late-stage gene therapy company, has reached ... Phase 3 study for inherited retinal dystrophies caused by mutations in ... , is presenting this and other corporate updates today, at the ... . Marrazzo said Spark was able to achieve its recruitment ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
(Date:4/23/2014)... - In a country as wealthy as the United States, ... seniors do not have access to adequate food due to ... insecure. , Recent research at the University of Illinois ... (NHANES) revealed that the seniors who are dealing with hunger ... "In 2011, 8.35 percent of Americans over age 60 faced ...
(Date:4/23/2014)... Effects of Midlife Occupational and Leisure Time Physical Activity ... physical activity in midlife increases the risk of mobility ... the risk. This is found in a study which ... The study was conducted at the Gerontology Research Center ... , Heavy physical labor is often repetitive, wears the ...
(Date:4/23/2014)... bottom of Alzheimer,s disease has been a rapidly ... In the latest crook in the research road, ... interaction between proteins associated with the disease. The ... Chemical Neuroscience , could have important implications for ... Nieznanski and colleagues explain that for years, research ...
(Date:4/22/2014)... the last few decades researchers have characterized a set ... and behavior in all types of species, from flies ... identified, but researchers surmise there are more. A team ... of Pennsylvania wondered if big-data approaches could find them. ... by John Hogenesch, PhD, professor of Pharmacology and first ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... Healthcare Each Sell Financially Challenged Facilities to ... ... HealthLeaders-InterStudy, NASHVILLE, Tenn., April 9, 2008 ,HealthLeaders-InterStudy, a ... ownership continue to,influence the Miami-area market as for-profit HCA Inc. ...
... Support Foundation Programs, MCLEAN, Va., April 9, ... announced the inaugural,Infinitive Championship Series. This unique series ... of running and triathlon races for,points and prizes. ... collect,points from series events in order to qualify ...
... possible to mimic the tactics used by parasites to ... , That is the hope of Dr Shane Grey ... John Dalton from the Institute for the Biotechnology of ... pair has been awarded a $400,000 grant through the ...
... could be missed, harming long-term survival, study suggests , , ... analysis of breast cancer patient survival suggests it might ... node biopsies. , A team of New York City ... to be free of cancerous cells in their sentinel ...
... a MED3OOO company,that delivers EHR technology to physician ... the Ohio State Medical Association,(OSMA), in Columbus, OH, ... by OSMA to help physician groups make the ... Standards of Excellence Program is available exclusively to,OSMA ...
... WASHINGTON, April 9, 2008 Global Health ... saving lives by improving,health throughout the world, ... Washington, D.C. and Vermont locations., Organizational ... implement a new software system to manage ...
Cached Medicine News:Health News:Miami Hospital Market Sees Shift in Ownership of Two Area Facilities 2Health News:Management Consultancy Announces Inaugural Infinitive Championship Series 2Health News:Manipulating the immune system like a parasite 2Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 2Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 3Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 4Health News:InteGreat Selected to Participate in OSMA's Standard of Excellence Program for EHRs 2Health News:InteGreat Selected to Participate in OSMA's Standard of Excellence Program for EHRs 3Health News:Global Health Council Selects Aptify's Association Management Software 2Health News:Global Health Council Selects Aptify's Association Management Software 3
... Ankle Cryo/Cuff combines the therapeutic benefits of ... and cold to minimize pain. The cuff ... ankle providing maximum cryotherapy. The Ankle Cryo/Cuff ... available in a pediatric size.,All Cryo/Cuffs can ...
... The Air-Stirrup Plus combines the ... an ankle wrap. In addition, a ... each Air-Stirrup Plus and provides information ... components of ankle sprain management.,Each Air-Stirrup ...
... Aircast VenaFlow System (a prophylaxis for DVT), ... styles: calf, foot, and thigh, to suit ... from light, cool, comfortable material to promote ... be placed directly against the skin. With ...
Comfor™ Cast Boot - Rocker Sole - Closed Toe...
Medicine Products: